#1 Clinical Trials Search in Europe

Tebentafusp

Tebentafusp is an innovative drug being studied in clinical trials for the treatment of advanced uveal melanoma, a rare and aggressive eye cancer. This article summarizes key information about ongoing clinical trials evaluating tebentafusp’s safety and effectiveness in patients with this challenging disease.

Table of Contents

What is Tebentafusp?

Tebentafusp is a new and promising medication designed to treat a rare type of eye cancer called uveal melanoma. It’s also known by the brand name Kimmtrak and the research name IMCgp100[1]. Tebentafusp is a type of drug called a bispecific T cell engager, which means it helps your immune system fight cancer cells[1].

How Does Tebentafusp Work?

Tebentafusp works in a unique way. It’s designed to bind to two different things at once:

  1. A protein called gp100 that is found on melanoma cancer cells
  2. A type of immune cell called a T cell
By connecting these two, tebentafusp helps your immune system recognize and attack the cancer cells[1]. This targeted approach is why tebentafusp is considered a breakthrough in treating uveal melanoma.

What Conditions Does Tebentafusp Treat?

Tebentafusp is primarily used to treat uveal melanoma, a rare type of eye cancer that develops in the colored part of the eye (iris, ciliary body, or choroid)[1]. It’s particularly useful for:

  • Advanced or metastatic uveal melanoma (cancer that has spread to other parts of the body, often the liver)[1]
  • Patients who have a specific genetic marker called HLA-A*02:01[1]
Some clinical trials are also exploring its use in other types of melanoma, including cutaneous (skin) melanoma[2].

How is Tebentafusp Administered?

Tebentafusp is given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The treatment schedule typically follows this pattern:

  • Week 1: 20 micrograms (mcg)
  • Week 2: 30 mcg
  • Week 3 and onwards: 68 mcg weekly
This gradual increase in dose is called a “step-up” dosing regimen and is designed to help your body adjust to the medication[3].

Clinical Trials and Research

Tebentafusp has shown promising results in clinical trials. In one major study, it was the first treatment to improve overall survival in patients with metastatic uveal melanoma[3]. This success has led to several ongoing studies exploring its use in different scenarios:

  • As an adjuvant therapy (treatment given after primary treatment to lower the risk of cancer coming back) in high-risk uveal melanoma[3]
  • In combination with other cancer treatments like immunotherapy or targeted therapies[2]
  • In earlier stages of uveal melanoma, before the cancer has spread[4]
Researchers are also studying how tebentafusp affects circulating tumor DNA (ctDNA), which are small pieces of DNA from cancer cells that can be found in the blood. This could help doctors monitor how well the treatment is working[1].

Potential Side Effects

Like all medications, tebentafusp can cause side effects. Some of the most common include:

  • Cytokine release syndrome (CRS): This is an immune reaction that can cause fever, chills, and other flu-like symptoms[2]
  • Skin reactions
  • Fatigue
  • Nausea
Your healthcare team will monitor you closely for these side effects and can provide treatments to manage them if they occur[3].

Future Directions

The success of tebentafusp in treating uveal melanoma has opened up new avenues of research. Scientists are now exploring:

  • Combining tebentafusp with other treatments, such as liver-directed therapies for patients whose cancer has spread to the liver[5]
  • Using tebentafusp earlier in the course of the disease, potentially to prevent the cancer from spreading[4]
  • Developing similar drugs that target other types of cancer[6]
These ongoing studies aim to further improve outcomes for patients with uveal melanoma and potentially expand the use of this innovative treatment approach to other cancers.

Aspect Details
Drug Name Tebentafusp (also known as IMCgp100)
Type of Drug Bispecific T cell engager that targets gp100 protein on melanoma cells
Main Indication Advanced or metastatic uveal melanoma
Patient Eligibility HLA-A*02:01 positive patients
Administration Intravenous infusion, typically weekly
Dosing Often uses a step-up dosing regimen (e.g. 20 mcg, 30 mcg, then 68 mcg)
Key Outcomes Measured Overall survival, progression-free survival, tumor response rate
Common Side Effects Fever, fatigue, skin rash, nausea, cytokine release syndrome
Ongoing Research Combination with other therapies, use in earlier disease stages

FAQ

  • What is tebentafusp? Tebentafusp is a bispecific protein drug that binds to both melanoma tumor cells and immune T-cells. This binding activates the immune system to attack the cancer cells.
  • What type of cancer is tebentafusp being studied for? Tebentafusp is primarily being studied for the treatment of uveal melanoma, a rare cancer that starts in the eye. It is being tested in patients with advanced or metastatic uveal melanoma.
  • How is tebentafusp given to patients? Tebentafusp is given as an intravenous (IV) infusion, usually once a week. The dose is often increased gradually over the first few weeks of treatment.
  • What are some of the potential side effects of tebentafusp? Common side effects may include fever, fatigue, skin rash, and nausea. A serious but manageable side effect called cytokine release syndrome can occur, especially with initial doses.
  • How long do patients typically receive tebentafusp treatment in clinical trials? Treatment duration varies, but many trials allow patients to continue receiving tebentafusp for up to 24 months or longer, as long as they are benefiting and not experiencing unacceptable side effects.

Ongoing Clinical Trials on Tebentafusp

  • Study on Tebentafusp and Liver Radiotherapy for Patients with Metastatic Uveal Melanoma HLA A*02:01 Positive

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of Tebentafusp for Patients with Metastatic Uveal Melanoma and Resectable Liver Metastasis

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Spain

  • Title: Comparing tebentafusp treatment versus observation in patients with high-risk eye melanoma (uveal melanoma) after initial treatment

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Ireland Italy The Netherlands +3

  • Study of Tebentafusp and Pembrolizumab for Patients with Previously Treated Advanced Melanoma

    Recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Italy Poland +1

  • Study on Tebentafusp and Drug Combination for Patients with Advanced Uveal Melanoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Italy Poland Spain

Glossary

  • Uveal Melanoma: A rare type of eye cancer that develops in the uvea, the middle layer of the eye that contains pigment cells.
  • Metastatic: Cancer that has spread from its original location to other parts of the body.
  • HLA-A*02:01: A specific version of a gene important for immune function. Patients must have this gene variant to be eligible for tebentafusp treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the cancer getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients diagnosed with a disease are still alive.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease that occurs during treatment, whether or not it is considered related to the treatment.
  • Cytokine Release Syndrome (CRS): A condition that can occur after certain immunotherapies, causing symptoms like fever, nausea, and difficulty breathing due to an overactive immune response.
  • Neoadjuvant Therapy: Treatment given before the main treatment, often to shrink a tumor before surgery or radiation.
  • Circulating Tumor DNA (ctDNA): Small pieces of DNA from tumor cells that can be found in a patient's blood and used to monitor cancer.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure if tumors are responding to treatment in cancer clinical trials.

References

  1. https://clinicaltrials.gov/study/NCT06070012
  2. https://clinicaltrials.eu/trial/study-of-tebentafusp-and-pembrolizumab-for-patients-with-previously-treated-advanced-melanoma/
  3. https://clinicaltrials.eu/trial/study-on-tebentafusp-for-patients-with-high-risk-uveal-melanoma-after-surgery-or-radiation/
  4. https://clinicaltrials.gov/study/NCT06414590
  5. https://clinicaltrials.gov/study/NCT06626516
  6. https://clinicaltrials.gov/study/NCT04262466